Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?

J Gynecol Oncol. 2020 Nov;31(6):e95. doi: 10.3802/jgo.2020.31.e95.
No abstract available

MeSH terms

  • Bevacizumab / therapeutic use*
  • Female
  • Humans
  • Ovarian Neoplasms* / drug therapy
  • Phthalazines / therapeutic use*
  • Piperazines / therapeutic use*

Substances

  • Phthalazines
  • Piperazines
  • Bevacizumab
  • olaparib